Sign In
Buy CMPX
$2.10
+0.0200 (+0.96%)
At Close: Jun 03, 2026
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
07:00am, Tuesday, 01'st Apr 2025
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical c
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
08:00am, Thursday, 27'th Feb 2025
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the firs
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 10'th Feb 2025
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Top 3 High-Momentum Companies Analysts Are Still Bullish On
07:03am, Tuesday, 04'th Feb 2025
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
12:20pm, Friday, 31'st Jan 2025
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 10'th Dec 2024
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
08:00am, Tuesday, 10'th Dec 2024
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
12:54pm, Monday, 09'th Dec 2024
Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
08:00am, Monday, 02'nd Dec 2024
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
10:35am, Thursday, 21'st Nov 2024
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
01:00pm, Friday, 15'th Nov 2024
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics to Participate in Upcoming Investor Events
08:30am, Wednesday, 13'th Nov 2024
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
08:00am, Tuesday, 12'th Nov 2024
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to
